# California Study Tracks Adolescent CUD After Cannabis Legalization > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/california-adolescent-cud-legalization-2026/ > **Published:** 2026-09-13T03:17:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:04-04:00 > **Clinical Summary:** Adolescent cannabis use disorder diagnosis trends changed around California legalization milestones in a large interrupted time-series study. --- CED Clinical Relevance #88 High Clinical Relevance A newly published population-based interrupted time-series study examined incident cannabis use disorder diagnoses among 637,461 adolescents before and after recreational cannabis legalization milestones in California. Clinical Insight | CED Clinic A health-system study followed monthly incident cannabis use disorder diagnoses among 637,461 Kaiser Permanente Northern California members aged 13 to 17 from January 2014 through February 2020. Diagnosis rates had been declining before legalization passage. The model identified an upward slope change six months after passage, followed by a negative slope change six months after retail sales began. The post-implementation trend continued upward but was not statistically significant. The findings support continued surveillance, but the abstract does not establish that legalization caused an individual diagnosis or identify the pathway behind the changes. Adolescent HealthCannabis Use DisorderCaliforniaLegalizationPublic Health AudienceParents, adolescents, clinicians, educators, policymakers, and cannabis-science readers Primary Topicadolescent cannabis use disorder diagnoses before and after recreational cannabis legalization in California Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42728108/) A population-based Northern California study found that adolescent cannabis use disorder diagnosis trends changed after legalization passage, while the trend after retail implementation remained statistically uncertain. What This Study Teaches Us The study adds diagnosis-based longitudinal surveillance to the legalization debate. It separates the law-passage milestone from retail implementation and shows why trend changes should be read with their confidence intervals and timing, not reduced to a single before-and-after claim. Why This Matters Adolescent cannabis use disorder can affect school, family life, mental health, and safety. Clinicians and policymakers need measures of disorder and clinical contact, not only whether a young person reports any cannabis use. Study SnapshotStudy TypePopulation-based interrupted time-series studyPopulation637,461 Kaiser Permanente Northern California members aged 13 to 17Observation WindowJanuary 2014 through February 2020OutcomeMonthly incident cannabis use disorder diagnoses from electronic health recordsPre-Passage TrendAdjusted rate ratio 0.95 per year, 95% CI 0.92 to 0.97Passage MilestoneUpward slope change after a six-month lag, aRR 1.26, 95% CI 1.14 to 1.38Retail MilestoneNegative slope change after a six-month lag, aRR 0.86, 95% CI 0.76 to 0.98Post-Implementation TrendaRR 1.02, 95% CI 0.96 to 1.09, not statistically significantPrimary BoundaryObservational diagnosis trends do not prove individual-level causationPMID / DOI42728108 / 10.1111/add.70597 Clinical Bottom Line Adolescent CUD diagnosis rates changed around California legalization milestones, but the pattern was not a simple continuous increase attributable to retail sales. The study supports monitoring, screening, and prevention while preserving uncertainty about causation and mechanisms. What the Researchers Measured Researchers counted new cannabis use disorder diagnoses each month among adolescents enrolled in a large Northern California health system from 2014 through early 2020. The analysis tested whether the direction of the monthly trend changed after legalization passage and after legal recreational sales began, each with a six-month lag. The Passage-Period Signal Before legalization passage, incident diagnosis rates were decreasing. The model then identified a statistically significant upward slope change after the passage milestone plus six months. This is a change in the modeled trend, not proof that the law caused a diagnosis in any particular adolescent. The Retail-Implementation Pattern After retail implementation plus six months, the model found a statistically significant negative slope change. The subsequent trend still pointed upward, but its confidence interval included no change. That pattern argues against describing the results as a simple, uninterrupted post-legalization rise. What the Abstract Cannot Resolve The abstract does not report cannabis exposure, product potency, retail access, screening intensity, coding changes, treatment engagement, or individual pathways to diagnosis. Those unreported details cannot be supplied from inference. The article therefore treats the findings as a surveillance signal rather than a causal verdict. How Strong Is This Evidence? The study used a large adolescent health-system population, monthly electronic health-record outcomes, and an interrupted time-series design that distinguished legalization passage from retail implementation. Where This Paper Deserves Skepticism The outcome was a recorded diagnosis, which can reflect both underlying disorder and contact or recognition within care. The abstract does not report individual cannabis exposure or the mechanisms behind the trend changes. What This Paper Does Not Show The study does not show that legalization caused cannabis use disorder in a particular adolescent, that retail sales alone drove the observed pattern, or that every California region and health system experienced the same trend. How This Fits With the Broader Clinical Conversation Legalization evaluations can produce different answers depending on whether they measure any use, frequent use, symptoms, diagnoses, emergency visits, or treatment entry. These outcomes should not be treated as interchangeable. A prevention response can remain evidence-based without overstating causality: screen adolescents confidentially, ask about frequency and consequences, support families, and monitor policy outcomes across multiple data sources. Dr. Caplan’s Take *The strongest lesson is methodological. The study did not find one uniform post-legalization line. It found a change after passage, then a different change after retail implementation, followed by a statistically uncertain trend.* *That complexity should improve clinical and policy conversations. Adolescents need early, nonpunitive screening and clear education about cannabis use disorder, while policymakers need surveillance that separates use, disorder, diagnosis, and access to care.* What a Careful Reader Should Take Away Treat this as a meaningful adolescent public-health signal that warrants monitoring, not as proof of a single causal pathway from legalization to diagnosis. Evidence Interpretation Guide Table of Contents - [How to Read the California Adolescent CUD Trend](#How_to_Read_the_California_Adolescent_CUD_Trend)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Eight Ways to Read the Adolescent CUD Signal](#Eight_Ways_to_Read_the_Adolescent_CUD_Signal)[A Diagnosis Trend Is Not a Personal Prediction](#A_Diagnosis_Trend_Is_Not_a_Personal_Prediction) - [Screen for Disorder, Not Only Exposure](#Screen_for_Disorder_Not_Only_Exposure) - [Concern Works Better When It Is Specific](#Concern_Works_Better_When_It_Is_Specific) - [Two Policy Milestones Produced Different Slopes](#Two_Policy_Milestones_Produced_Different_Slopes) - [Measure More Than Prevalence](#Measure_More_Than_Prevalence) - [Health-System Data Show One Important Slice](#Health-System_Data_Show_One_Important_Slice) - [Early Identification Should Remain Nonpunitive](#Early_Identification_Should_Remain_Nonpunitive) - [Connect Diagnosis Trends to Exposure and Care](#Connect_Diagnosis_Trends_to_Exposure_and_Care) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read the California Adolescent CUD Trend Interrupted time-series studies estimate whether a trend changes around a defined policy milestone. The results are most useful when each segment, lag, and confidence interval is kept visible. ### A Four-Step Reading Frame **Evidence type**This was an observational interrupted time-series analysis, not a randomized policy experiment. **Population**The sample included adolescent members of Kaiser Permanente Northern California, not every California adolescent. **Outcome meaning**The outcome was an incident CUD diagnosis recorded in the electronic health record, not a survey measure of any cannabis use. **Timing and uncertainty**The passage and retail milestones had different modeled slope changes, and the later trend was not statistically significant. The Research Question How did monthly incident adolescent cannabis use disorder diagnosis trends change around California legalization milestones? The Family Question Does this study prove that legalization caused a young person’s cannabis use disorder? The Bottom Line No. It identifies population-level diagnosis trend changes that support surveillance and screening, while individual causation remains unproven. CED Perspective Lens ## Eight Ways to Read the Adolescent CUD Signal What changed around California legalization milestones, and what remains uncertain Lens OverviewEach lens translates the time-series findings into a practical question while keeping the diagnosis-based, observational design in view. #### A Diagnosis Trend Is Not a Personal Prediction The study describes diagnosis patterns across a large health-system population. It does not predict which adolescent will develop cannabis use disorder, and it does not report an individual cannabis product, dose, or frequency threshold. Young people deserve confidential, nonpunitive conversations about use, craving, loss of control, school or family effects, and attempts to cut down. A population signal should open a door to support, not become a label applied without assessment. Lens takeawayUse the population signal to support earlier conversation, not personal assumptions or punishment. #### Screen for Disorder, Not Only Exposure The study outcome was an incident cannabis use disorder diagnosis, which is more clinically specific than a yes-or-no measure of cannabis use. That distinction matters when interpreting legalization research. Clinicians can ask about frequency, craving, unsuccessful efforts to reduce use, role impairment, tolerance, withdrawal, and continued use despite problems. The abstract does not test a screening program, but the diagnosis trend supports keeping adolescent CUD assessment visible in routine care. Lens takeawaySeparate any cannabis exposure from symptoms that indicate clinically meaningful loss of control. #### Concern Works Better When It Is Specific Families may hear legalization findings as a broad warning, but this study does not show that every adolescent who uses cannabis will develop a disorder. It follows diagnosis rates across time in one health system. More useful questions focus on observable change: declining school function, secrecy, escalating frequency, driving or riding with an impaired driver, mood changes, or repeated failed attempts to stop. Calm, specific concern is more likely to preserve communication than accusation based on a population statistic. Lens takeawayFocus family conversations on function, safety, and change rather than a generalized legalization claim. #### Two Policy Milestones Produced Different Slopes The researchers modeled legalization passage and retail implementation as separate interruptions, each with a six-month lag. The upward change after passage and negative change after implementation are both part of the reported pattern. The later segment still pointed upward, but it was not statistically significant. Readers should resist selecting only one coefficient. Interrupted time-series evidence is strongest when the pretrend, each interruption, the posttrend, and the confidence intervals are interpreted together. Lens takeawayRead the full segmented pattern instead of turning one slope change into the whole story. #### Measure More Than Prevalence Legalization surveillance often emphasizes whether adolescents report any past-month or past-year use. This study shows the added value of tracking incident disorder diagnoses as a separate clinical outcome. Diagnosis data also have boundaries. They can be influenced by care access, screening, documentation, and coding, although those pathways are not described in the abstract. Policymakers should compare multiple measures, including use, frequent use, symptoms, diagnoses, acute care, treatment access, and school outcomes. Lens takeawayA credible policy dashboard needs several youth outcomes, not one prevalence or diagnosis metric. #### Health-System Data Show One Important Slice The cohort was large and mostly non-White, but it included members of one Northern California health system. Adolescents outside that system may differ in access, diagnosis, insurance, geography, and exposure to local markets or prevention programs. The abstract does not provide subgroup trend results, so this article does not infer racial, ethnic, economic, or regional differences. Future surveillance should test whether diagnosis and treatment pathways are distributed fairly and whether policy effects differ across communities. Lens takeawayDo not generalize one health systems trend to every California adolescent or community. #### Early Identification Should Remain Nonpunitive A rise in recorded CUD diagnoses can represent more disorder, more recognition, or some combination, and the abstract does not resolve those pathways. Either way, adolescents with symptoms need timely assessment and support. Safety-focused care should include confidential screening, mental-health review, driving and passenger risk, product and frequency questions, and referral when symptoms impair daily life. The study does not test these interventions, but it reinforces the importance of monitoring disorder rather than treating any use as the only endpoint. Lens takeawayBuild early identification around confidentiality, function, and access to care rather than punishment. #### Connect Diagnosis Trends to Exposure and Care Future work can link policy timing with individual cannabis exposure, frequency, product potency, symptoms, screening practices, diagnosis, treatment entry, and outcomes. Longer follow-up could clarify whether the post-implementation pattern changes over time. Replication in diverse health systems, states, and regions nationwide would test generalizability. Studies should also examine how enforcement, retail density, marketing, prevention, and care access shape outcomes without assuming that one policy milestone acts through a single pathway. Lens takeawayThe next step is longitudinal, multisystem research connecting exposure, recognition, treatment, and policy context. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=California+Study+Tracks+Adolescent+CUD+After+Cannabis+Legalization&url=https%3A%2F%2Fcedclinic.com%2Fcalifornia-adolescent-cud-legalization-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcalifornia-adolescent-cud-legalization-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=California+Study+Tracks+Adolescent+CUD+After+Cannabis+Legalization%20https%3A%2F%2Fcedclinic.com%2Fcalifornia-adolescent-cud-legalization-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Adolescent cannabis use disorder following recreational cannabis legalization in California, USA: A population-based interrupted time series study.](https://pubmed.ncbi.nlm.nih.gov/42728108/) Related Reading at CED ClinicContinue exploring the evidence[Cannabis Legalization Outcomes: What 329 Studies Found](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/) A broad systematic review of legalization outcomes and the importance of regulatory design and measurement. [Review legalization evidence](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/)[Solitary Cannabis Use in Teens: What a Norwegian National Study Found](https://cedclinic.com/solitary-cannabis-use-teens-norway/) A national adolescent study on solitary cannabis use and negative-consequence screening signals. [Review adolescent evidence](https://cedclinic.com/solitary-cannabis-use-teens-norway/)[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) National adult trend context for cannabis use disorder and routine screening. [Review CUD trends](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) Similar Studies on CEDClinic.comEarlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [Cannabis Legalization Outcomes: What 329 Studies Found](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/) A broad systematic review of legalization outcomes and the importance of regulatory design and measurement. [Review legalization evidence](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/) Related digest item [Solitary Cannabis Use in Teens: What a Norwegian National Study Found](https://cedclinic.com/solitary-cannabis-use-teens-norway/) A national adolescent study on solitary cannabis use and negative-consequence screening signals. [Review adolescent evidence](https://cedclinic.com/solitary-cannabis-use-teens-norway/) Related digest item [Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) National adult trend context for cannabis use disorder and routine screening. [Review CUD trends](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) ## Frequently Asked Questions Who was included in the study? The study included 637,461 Kaiser Permanente Northern California members aged 13 to 17 years from January 2014 through February 2020. What outcome did the researchers measure? They measured the monthly count of incident cannabis use disorder diagnoses recorded in electronic health records. What was happening before legalization passage? Before passage, adolescent CUD diagnosis rates were decreasing, with an adjusted rate ratio of 0.95 per year. What changed after legalization passage? After passage plus a six-month lag, the model found a statistically significant upward slope change, with an adjusted rate ratio of 1.26. What changed after retail sales began? After retail implementation plus a six-month lag, the model found a statistically significant negative slope change, with an adjusted rate ratio of 0.86. Did diagnosis rates keep increasing after retail implementation? The subsequent trend pointed upward, but it was not statistically significant because the 95% confidence interval included no change. Does the study prove legalization caused adolescent CUD? No. The observational time-series design identifies population-level trend changes but does not prove individual-level causation. Does a CUD diagnosis equal any cannabis use? No. Cannabis use disorder is a clinical diagnosis, while any cannabis use is a broader exposure measure. Was the full article reviewed? No. No PMC or Unpaywall full text was available, so study-specific claims are limited to the peer-reviewed abstract and identifier record. What is the practical takeaway? Continue confidential adolescent screening, distinguish use from disorder, and monitor multiple public-health outcomes without overstating causation. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).